Table 2.
Univariate and multivariate analyses of progression-free survival in NSCLC patients with osimertinib treatment (n = 71).
| Characteristics | HR (95% CI)* | P value | Adjusted HR (95% CI)* | P value |
|---|---|---|---|---|
| Age | ||||
|
< 65 ≥ 65 |
Reference 1.49 (0.68–3.24) |
0.316 | 1.61 (0.68–3.78) | 0.276 |
| Gender | ||||
|
Female Male |
Reference 0.99 (0.46–2.12) |
0.969 | 0.67 (0.14–3.07) | 0.602 |
| Smoking status | ||||
|
C/FS NS |
Reference 1.46 (0.62–3.46) |
0.391 | 1.07 (0.22–5.35) | 0.931 |
| ECOG PS | ||||
|
2–3 0–1 |
Reference 0.21 (0.07–0.65) |
0.007 | 0.14 (0.04–0.50) | 0.002 |
| Stage | ||||
|
Recurrence Stage IVA Stage IVB |
Reference 0.90 (0.24-3.41) 1.58 (0.45–5.47) |
0.871 0.474 |
1.09 (0.26–4.53) 1.45 (0.27–7.68) |
0.909 0.665 |
| Brain metastasis at baseline | ||||
|
No Yes |
Reference 1.92 (0.89–4.14) |
0.095 | 1.16 (0.29–4.63) | 0.834 |
| Baseline EGFR mutation status | ||||
|
Exon 21 L858R Exon 19 deletion |
Reference 0.30 (0.14–0.64) |
0.002 | 0.24 (0.10–0.57) | 0.001 |
| PD-L1 expression level | ||||
|
PD-L1≧50% PD-L1 < 50% |
Reference 0.23 (0.09–0.60) |
0.002 | 0.19 (0.06–0.67) | 0.009 |
NSCLC, non-small-cell lung cancer; HR, hazard ratio; CI, confidence interval; C/FS, current/former-smokers; NS, never smoker; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; PD-L1, Programmed death-ligand 1.
*By Cox proportional hazard model.